Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
MD Anderson Receives Nearly $23 Million in CPRIT Funding for Cancer Research, Faculty Recruitment
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
Identifying and Addressing the Overlooked Need of Patient Sexual Health
Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management
2 Commerce Drive
Cranbury, NJ 08512